ARTICLE | Clinical News
Genfit preclinical data
February 24, 2014 8:00 AM UTC
In vitro, GFT505 blocked proliferation of cancer cells in the majority of 21 human cancer cell lines. The cell lines originated from myeloproliferative disorders and meningiomas, leukemia, gastrointestinal, lung, pancreatic, skin, colon, breast, thyroid and prostate cancers. Genfit could not be reached for next steps for GFT505 in cancer. ...